Abstract
The synchronization of the donor stimulation with the endometrial preparation of the
recipient is usually done by downregulating the recipient's pituitary with a GnRH
analog.
Objective
The aim of this study is to compare pregnancy and implantation rates among premenopausal
oocyte recipients synchronized by pituitary suppression with GnRH agonist (Group AGO)
or antagonist (Group ANTAG) and standard endometrial preparation with estrogen and
gestagen.
Study design
Prospective, observational, transversal, comparative study. Consecutive recipients
treated at Institut Universitari Dexeus between July 2008 and December 2009.
Results
One hundred and eighty-three premenopausal women were included. No differences were
found regarding the age of donors nor the age of recipients, fertilization rates,
number of embryos transferred and embryo quality. No differences were found in clinical
pregnancy rates (56.1% Group AGO vs. 52.4% Group ANTAG).
Conclusion
The administration of GnRH antagonists during endometrial preparation in oocyte recipients
facilitates synchronization without affecting the pregnancy rate.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Obstetrics and Gynecology and Reproductive BiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure.Nature. 1984; 307: 174-175
- A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH.Hum Reprod. 2006; 21: 2121-2125
- Oocyte and embryo donation 2006: reviewing two decades of innovation and controversy.RBM Online. 2006; 12: 153-162
- Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients.Gynecol Endocrinol. 2008; 24: 188-193
- GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study.Hum Reprod. 2005; 20: 1516-1520
- GnRH antagonists in ovarian stimulation for IVF.Hum Reprod Update. 2006; 12: 333-340
- Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial.Hum Reprod. 2006; 21: 2246-2251
- Randomised, comparative pilot study of pituitary suppression with depot leuproreline vs Cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors.Fertil Steril. 2010; 94: 2433-2436
- Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.Gynecol Endocrinol. 2009; 25: 60-66
- Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study.Fertil Steril. 2010; 93: 2418-2420
- GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial.Reprod Biomed Online. 2009; 18: 276-281
- Endometrial preparation for frozen–thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist.Fertil Steril. 2002; 77: 956-960
- Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study.Hum Reprod. 2004; 19: 874-879
- Cycle regimens for frozen–thawed embryo transfer.Cochrane Database Syst Rev. 2008; 23: CD003414
- Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists.Hum Reprod. 2000; 15 ([review]): 1211-1216
- A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon).Hum Reprod. 1998; 13: 3023-3031
- Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturarion on the day of oocyte pick-up.Fertil Steril. 2002; 78: 1025-1029
- Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.Hum Reprod. 2005; 20: 1541-1547
- GnRH antagonists may affect endometrial receptivity.Fertil Steril. 2008; 89: 1234-1239
- Similar endometrial development in oocyte donors treated with either high-or standard dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles.Hum Reprod. 2005; 20: 3318-3327
- Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro.Hum Reprod. 2009; 24: 2187-2192
- Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor.RBM Online. 2008; 17: 237-243
- Luteal phase support for patients undergoing frozen–thawed embryo transfer cycles: the required progesterone dose.Clin Exp Obstet Gynecol. 2007; 34: 25-26
Article info
Publication history
Published online: June 27, 2011
Accepted:
June 9,
2011
Received in revised form:
May 10,
2011
Received:
February 10,
2011
Identification
Copyright
© 2011 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
